Growth intact, but sequential deceleration signals headwinds ahead
The year-on-year numbers are impressive — ₹162.4 crore revenue (+45.6%), PAT up 115% — but quarter-on-quarter growth stalled at just +3.5%. Management reaffirmed FY27 guidance rather than raise it, a tacit admission that near-term catalysts are deferred to FY28–FY30.
₹162.4 Cr
+45.6% YoY (vs. ₹111.5 Cr Q1 FY26)
₹25.6 Cr
+115% YoY (vs. ₹11.9 Cr Q1 FY26)
+3.5%
Q1 vs. Q4 FY26 ~₹157 Cr
25.3%
in line with 26–27% FY27 guidance
The year-on-year punch is real. Kwality's Q1 growth story is genuine — revenue up 45.6%, PAT up 115%, underpinned by geographic expansion (LATAM 35–40% of revenue), oncology volumes, and a broader recovery in regulated injectable markets. The net profit margin at 15.7% is solid for the sector. But the quarter-on-quarter deceleration tells a different story: just +3.5% sequential growth suggests base effects, working capital churn in MENA (geopolitical disruption), and the absence of new revenue catalysts in the near term.
The delivery vs. guidance dynamic
Q1 ₹162.4 crore annualizes to ₹649.6 crore — squarely at the lower end of management's ₹650–700 crore FY27 guidance. This is a Met, not a Beat. What's telling is that management reaffirmed guidance rather than raised it, narrowing the range from ₹650–700 Cr to ₹700+ Cr (signalling confidence at the high end but implying limited upside). On the call, they gave a clear explanation: oncology registrations are delayed to Q4 (were expected Q3), hormone plant commissioning is Nov with GMP approval only June 2027, and Erythropoietin (biosimilar, Unit 5) clinical trials don't start until Nov. In other words, all the multiyear growth catalysts are pushed into FY28–FY30.
Q1 on track for ₹700+ Cr FY27 guidance
Supported₹162.4 Cr Q1 annualizes to ₹649.6 Cr, at lower end of ₹650–700 Cr range. FY27 guidance reaffirmed as ₹700+.
Oncology will be 25–30% of mix by FY27
OverstatedOncology at 20% in Q1 (down from 26% prior guidance). Registrations delayed to Q4 FY27. Management reaffirms ₹100 Cr FY27 target but acknowledges timeline slip.
Gross margins will expand despite 53% Q1
ContradictedAt ₹700 Cr revenue, management now guides 49–51% gross margins (down from legacy 60%+). ROW market mix (35–40% of revenue) is structurally dragging margins. Will only improve at much higher scale.
Erythropoietin in ROW markets by end CY27
OverstatedPre-clinical just completed; clinical trials starting Nov 2026. 4-month PK/PD study, registrations by Nov–Dec 2027. ROW revenue push to FY29–FY30, not CY27.
60–70 registrations in last 3 quarters, 2–3 per quarter ongoing
SupportedMexico pipeline: 70 submitted, 18–19 registered. Expecting 6–7 registrations Q2 onwards. Mechanism credible but execution risk remains.
What changed on this call
Three upgrades and three downgrades. On the upside: management confirmed a more ambitious long-term target — ₹1,500 crore by FY30 (upgraded from the prior ₹1,000 crore aspiration for FY29), driven by biosimilar Erythropoietin (₹200–250 Cr), hormone launch (₹150–200 Cr), and sustained generics growth. The Keytruda (Pembrolizumab) biosimilar R&D is complete; pre-clinical studies end by March 2027, clinical trials begin April 2027, and launch is targeted before CY28 patent expiry — positioning Kwality for the first wave. On the downside: oncology registrations delayed from Q3 to Q4 FY27 (material 9-month slip). Gross margins will remain depressed at 49–51% at the ₹700 Cr revenue target due to ROW mix headwinds. Working capital is still stretched — ₹300 crore (40% of ₹700 Cr revenue) is trapped in receivables at 165–170 debtor days, mostly from MENA/CIS disruption in FY26.
The market's read — price, flows, and valuation
The market liked the result. The stock rallied +5.67% on day 1 post-announcement, +6.42% by day 3, and +15.02% by day 5, with the momentum holding through the five-day window — a signal that the market accepted both the reported numbers and the forward guidance. Foreign institutional investors added 0.34 percentage points of ownership (FII rose from 2.79% to 3.13% QoQ), suggesting confidence in the multiyear growth story. But valuation is at risk. The stock at ₹3,515 is up 324% from its 52-week low (₹828.8) and sits just 5.65% below its all-time high (₹3,725.45). RSI at 82.3 signals overbought conditions. Any stumble on FY28 execution — missed registration targets, hormone delays beyond June GMP, biosimilar timeline slips — could trigger a sharp correction given the elevated multiple investors are paying for a 3–5 year growth story.
Strong YoY growth (+45.6% revenue, +115% PAT) and on-track for ₹700 Cr FY27
Dossier model + PIC/S certification enable 60–70 registrations/year; rare moat in Indian generics
Multiyear catalysts quantified (hormone ₹150–200 Cr, Erythropoietin ₹200–250 Cr, Keytruda in race to market)
QoQ growth has stalled (+3.5%), suggesting base effects and working capital churn
Gross margin compression is structural (53% Q1, will be 49–51% at ₹700 Cr); legacy 60%+ not recoverable at current scale
All major near-term catalysts delayed 6–12 months (oncology Q4 vs. Q3, hormone GMP June vs. Q4, biosimilar Nov clinical start)
Working capital stretched: ₹300 Cr receivables at 165–170 debtor days, majority from geopolitically risky MENA/CIS markets
Valuation is elevated: stock +324% from low, RSI 82.3 overbought, limited room for execution missteps
Registration pipeline execution (6–7/quarter target)
HighEach registration contributes ₹1.5–2 Cr annual revenue. A miss of even 2–3/quarter would compress ₹20–40 Cr from FY28 and create a domino effect on FY30 ₹1,500 Cr target. No buffer in guidance; registrations are the core growth engine.
Gross margin compression (structural, not temporary)
HighROW market mix (35–40% of revenue) forces 49–51% gross margins at ₹700 Cr; legacy 60%+ was domestic-heavy. At 15–20% EBITDA margin, every 100 bps of gross margin compression = ₹7 Cr EBITDA loss. Unlikely to recover unless LATAM/MENA shift to higher-margin regulated products.
Working capital strain (MENA/CIS receivables cycle)
Medium₹300 Cr (40% of ₹700 Cr FY27 revenue) trapped in 165–170 debtor days. Geopolitical risk (Yemen, Syria, CIS sanctions) could push to 180–200 days, locking ₹50–100 Cr. No factoring facility drawn to date; assumes payment normalization.
Near-term catalyst delays (hormone GMP, Erythropoietin, oncology registrations)
MediumOncology registrations delayed 9 months (Q3 → Q4). Hormone GMP approval risk June 2027; if delayed to Q3/Q4, ROW tender sales (₹70–80 Cr FY28 baked into guidance) slip to FY29. Erythropoietin bioequivalence outcome uncertain; 6–12 month further slips are credible.
Biosimilar clinical trial execution (Keytruda, Erythropoietin, 3 molecules)
Medium₹150 Cr capex spread over FY28–FY29 for clinical trials. 1.5–2 year timelines per molecule. Keytruda patent expires CY28; any delay past Q2 2028 launch means competitive entry risk. Clinical failure on any molecule = ₹50+ Cr sunk cost.
Valuation is overbought (RSI 82.3, +324% from low, near ATH)
MediumStock has priced in most of the FY28–30 upside. A Q2–Q3 miss on registrations or a reaffirmation of FY28 guidance (not raised) could trigger 15–20% drawdown. Limited margin of safety for retail/institutional flow reversal.
1 · Q2 FY27 registration run-rate (target: 6–7 approvals)
Will determine credibility of ₹875–910 Cr FY28 guidance (25–30% growth). Any shortfall (<4 approvals) signals pipeline execution risk. Expect Mexico, Colombia, Saudi Arabia, MENA updates.
2 · Hormone plant GMP approval timeline (target: June–July 2027)
Slippage to Q3/Q4 would defer ROW tender sales (₹70–80 Cr FY28 baked in). GMP approval is gating factor for bioequivalence and international registrations. Status updates in Q2/Q3 calls will clarify ₹150–200 Cr FY29 probability.
3 · Working capital recovery (debtor days trend toward 165–170 target)
MENA payment normalization is the key. Monitor quarterly receivables balance (₹300 Cr at 165–170 days = healthy; >₹350 Cr = concern). Any further slippage to 180–200 days signals geopolitical risk crystallizing and will compress free cash flow needed for capex.
Kwality delivered Q1 in line with guidance, not ahead of it. The 45.6% YoY growth is genuine, the net margin is solid at 15.7%, and the long-term roadmap to ₹1,500 Cr by FY30 is credible if execution holds. But the 3.5% QoQ deceleration, the cascade of catalyst delays (oncology, hormone, biosimilar), and the structural margin compression signal that this is not a step-change quarter — it's a steady continuation of a multiyear execution cycle. The market has priced in most of the upside (stock RSI 82.3, near ATH, FII inflow). Any stumble on FY28 registrations or working capital management will punish the multiple. The number to track from here is gross margin trend at the product level (is the 49–51% ₹700 Cr guidance holding, or compressing further?) and the sequential registration pace (is it 6–7/quarter or lower?). If both hold, the ₹1,500 Cr by FY30 story plays out. If either falters, the stock could correct 15–20% before the market re-rates lower.
Growth tracked, but catalysts deferred — FY30 ambition clear
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
Met prior FY27 guidance midpoint; reaffirms ₹650-700 Cr range. Oncology delayed (25-30% vs 30%), hormone FY29 pushed to FY30.
Optimistic
next 1–2 quarters
Very Optimistic
multi-year
Q1 delivery solid (₹162.4 Cr, +45.6% YoY) and on track for ₹700 Cr FY27 guidance, but sequential growth decelerating (+3.5% QoQ). Near-term catalysts (hormone launch, biologics trials, oncology registrations) deferred to FY28-FY30; execution risk on registrations and regulatory timelines remains the key constraint.
₹162.4 Cr
Revenue · +45.6% YoY₹25.6 Cr
Reported PAT · +115% YoYCompressing
Margins · vs guidance: CorroboratedDid the claims hold up?
Q1 on track for ₹700+ Cr FY27 guidance
MET₹162.4 Cr Q1 annualizes to ₹649.6 Cr, at lower end of ₹650-700 range
Oncology will be 25-30% by FY27 (vs prior 30% target)
OVERSTATEDQ1 oncology at 20%, down from 26%; registrations delayed to Q4
60-70 registrations in last 3 quarters, 2-3 per quarter ongoing
METMexico 70 submitted/18-19 registered; expecting 6-7 in Q2; mechanism credible
Erythropoietin in ROW market by end of CY27, ₹200-250 Cr by FY29
OVERSTATEDPre-clinical just completed, clinical trials starting Nov 2026, registrations push to FY29/30
Gross margins will expand despite current 53% (down from 56-57%)
MISSAdmitted margins will remain low at ₹700 Cr (49-51%), improve only at higher scale to 47%
Earnings quality
What changed since the last call
Oncology commercialization timeline
DowngradeRegistrations pushed from Q3 FY27 to Q4 FY27; 20% mix in Q1 (vs prior 26%), management acknowledges delayed approvals but reaffirms ₹100 Cr FY27 target
Long-term revenue ambition
UpgradePrior ₹1,000 Cr by FY29 aspiration → now ₹1,500 Cr by FY30 target confirmed (management said '100% right' to ₹1,400-1,500 Cr by FY30)
FY27 revenue guidance
NeutralPrior ₹650-700 Cr → now '₹700+ Cr'; reaffirmed at upper end, no increase in quantum but narrower range signals confidence
Hormone revenue FY29
NeutralPPT shows ₹150 Cr 'potential'; call clarified ₹150-200 Cr range (lower for conservative guidance, upside if registrations timely)
The Q&A
Q&A was adversarial on execution: analysts pressed on why oncology mix fell, why catalysts delayed, why hormone guidance ranges. Management held firm on FY27 ₹700 Cr but acknowledged timing slippage on biosimilar and hormone launches to FY28-FY30. Weak pushback on governance (KPMG audit timing, Kaler Biopharma deal vaguely dismissed).
Oncology mix decline — Aryan Mehta, Shravas Capital
Answered25-30% expected; registrations delayed to Q4 FY27. Got MENA/LATAM registrations instead (Mexico, Algeria, Morocco, Tunisia). Competitive edge from 60-70 dossiers and multi-plant PIC/S certification.
Erythropoietin (Unit 5) launch — Aryan Mehta, Shravas Capital
AnsweredIndia immediate post-approval; ROW markets can file after 4-month PK/PD study (40 patients), by Nov-Dec 2027 10-12 countries registered. Already filed in ~10 geographies.
KPMG auditor appointment — Utkarsh Somaiya, Elko Quantum
AnsweredQ3 or Q4 FY27 (filed agreement). Waiting for software upgradations to provide data in their format.
FY28-30 growth outlook — Utkarsh Somaiya, Elko Quantum
Answered25-30% growth expected FY28+; by 2030 ₹1,500 Cr target (doubling by FY30). EBITDA 26-27% FY27, reaching 30% by FY29 (linear 100bps/year possible).
Registration runrate acceleration — Nishita, Sapphire Capital
AnsweredExpecting 6-7 registrations Q2 onwards. Mexico targeting 5 more; Saudi Arabia, Colombia, Chile ramping. MENA/GCC expected to be highest % in Q4.
Hormone facility ramp — Nishita, Sapphire Capital
AnsweredManufacturing license Nov 2026; GMP June-July 2027 after 6-month stability. ROW tender sales possible immediately with license (₹70-80 Cr FY28). Full potential ₹150-200 Cr FY29 post-bioequivalence.
BE programs timeline — Nirali Shah, Ashika
Answered6-7 molecules commercialized by Q4 FY27; remaining 32 finished by Nov-Dec, filed in Q1-Q2 FY28. ₹80-100 Cr FY28 revenue; FY29 jump to ₹400-500 Cr.
Keytruda (Pembrolizumab) biosimilar status — Nirali Shah, Ashika
AnsweredR&D completed, cell line transferred to Kwality. Pre-clinical studies Dec 2026-March 2027; clinical trials start April 2027 (1-1.5 years); launch by end of CY 2028 (before patent expiry). Will be in first wave.
Debtor days and working capital — Nirali Shah, Ashika
PartialTarget 165-170 days by FY27-end (from 208). Payment cycle from MENA/CIS/GCC improving; recently got payments. At ₹700 Cr revenue, expect ₹300 Cr debtors (~40% of revenue).
Competitive moat (complex injectables) — Nirali Shah, Ashika
AnsweredCore moat is ability to imitate reference product formulation. Ampho B liposomal = 2nd generic; Octreotide LAR = 1st generic in 70% markets; Leuprolide = 1st in 75-80%. Formulation development + batch failures + R&D persistence key.
Gross margin contraction — Abhijeet, Paul Asset
AnsweredImproved QoQ (56-57% → 53%). At ₹700 Cr revenue should be 49-51%; ideal 47% with BE products. ROW market mix (35-40% revenue) dragging margins down.
Raw material inflation risk — Abhijeet, Paul Asset
Answered80-85% procurement from domestic API; only 15% China. No significant disruption to date.
Receivables recovery — Abhijeet, Paul Asset
AnsweredReceivables normalizing to 165-170 days (from 208); yes, ~40% of ₹700 Cr = ₹300 Cr in receivables by FY27-end.
Capex plan and debt — Abhijeet, Paul Asset
AnsweredTook extended loan but not utilizing. Will use ₹15-20 Cr only if cash flow disrupts. Current cash sufficient: hormone Nov, oncology March; biologics clinical trials Q2-Q3. Capex ₹185-190 Cr FY27 (hormone ₹70, oncology ₹50, BE ₹25-30, WC ₹20, R&D ₹10-15). Biosimilar clinical trials need ₹150 Cr in FY28-FY29.
Capex breakup — Abhijeet, Paul Asset
AnsweredHormone ₹70 Cr, Oncology ₹50 Cr, BE ₹25-30 Cr, WC ₹20 Cr, R&D ₹10-15 Cr = ₹185-190 Cr total.
Algerian JV for biosimilars — Abhijeet, Paul Asset
AnsweredJoint venture: partner invests in fill-finish plant; Kwality provides technology/clinical data (equity stake). APIs, registrations from Kwality. Parallel registration path: dossier without clinical data submitted to get stability batch approval in Algeria; clinical data submitted later. Also exploring Mexico/LATAM JVs.
Hormone revenue guidance conservatism — Manan, Wallfort Fund
AnsweredWill be ₹150-200 Cr depending on registrations. Guidance conservative (lower number) to avoid queries; upside if timely registrations.
500L bioreactor capacity — Manan, Wallfort Fund
Answered100L approved by CDSCO; 500L already installed (5× capacity). 500L approval pending, not rushing (only taking clinical batches now). Will register post-clinical batches done.
FY30 revenue potential — Manan, Wallfort Fund
AnsweredFY29 ₹1,000 Cr base (excludes biologics/hormone); FY30 with biologics ₹200-250 Cr + hormone ₹150-200 Cr + generics growth = ₹1,400-1,500 Cr possible. '100% right' it's achievable.
Unit 5 (Erythropoietin) by FY29 — Hemaant, Individual
PartialFY28 ₹80-100 Cr (India only); FY29 international registrations ₹200-250 Cr (may slip to FY30). Domestic + international by FY29 = ₹280-350 Cr potential if on time.
Hormone Unit 6 FY29 revenue — Hemaant, Individual
DodgedIf BE finishes on time post-GMP, then 100% achievable. But uncertain; if registrations slip, only ₹60-70 Cr from ROW tenders. FY28 or FY29 timing unpredictable.
Capacity utilization — Achal Maheshwari, Naredi
AnsweredGeneral 75-80%; Oncology 75-80%; Cepha/Beta 20-25%; Biologics not commercialized. Oncology expansion will add 45-50%; general facility extension will add 20%.
Oncology FY27 revenue target — Kunal Dube, Individual
AnsweredMaintaining ₹100 Cr target. Q3-Q4 expect more generic registrations than oncology. Expect ₹100-110 Cr from oncology; bigger jump from generics.
Oncology expansion revenue timing — Kunal Dube, Individual
AnsweredImmediate revenue. Will submit expansion to each ministry (Europe, Hungary, INVIMA Brazil, Colombia); can use same registrations without re-audit. Start commercializing right away.
Exclusion of biologics/hormone from FY29 guidance — Saurabh Gupta, Financially Free
AnsweredBiological commercializes FY28+, hormone FY28+. Since clinical trials ongoing, included in FY30 plans, not FY29. Hormone ROW sales possible <₹80 Cr if early; not adding to FY29 guidance.
Promoter stake increase — Saurabh Gupta, Financially Free
DodgedProbably will plan something. Did buyback in Q3 FY26 but no current plan.
FY30 revenue mix — Subhanu Bangal, 3 Head Capital
AnsweredGenerics 35-40% (LATAM 30-35%, Europe 10-15%, MENA 15-20%, GCC 10-15%). Oncology 25%, Biosimilar 15-30% (if Keytruda launched), Hormone 15-20%, Beta-lactam/Cepha 10-15%. India upside once biosimilar commercialization starts.
Guidance
FY27 ₹700+ Cr (reaffirmed from ₹650-700 Cr prior range)
HighQ1 ₹162.4 Cr annualizes to ₹649.6 Cr; management stated multiple times '100% confident' ₹700+ Cr achieved. LATAM 35-40%, generics acceleration driving.
FY28 ₹875-910 Cr (25-30% growth from FY27 base)
MediumContingent on 6-7 registrations per quarter; hormone commercialization Nov, Erythropoietin India launch; oncology expansion
FY29 ₹1,000-1,100 Cr (excluding biologics/hormone material contribution)
MediumGenerics core growth; biologics/hormone kept separate as 'discretionary upside' due to R&D/regulatory delays
FY30 ₹1,400-1,500 Cr (including biosimilar Erythropoietin ₹200-250 Cr, hormone ₹150-200 Cr, Keytruda upside)
MediumContingent on timely registrations (6-7/quarter), Keytruda launch by CY28, hormone bioequivalence. Management said '100% right' and '100% possible'.
EBITDA FY27 26-27% (maintained from prior guidance)
HighQ1 OPM 25.3%; inline with full-year 26-27% target. Margins will compress at ₹700 Cr (49-51% gross) due to ROW product mix.
EBITDA FY28-29 linear progression to 30% by FY29
Medium~100bps improvement per year as scale increases and ROW mix shifts to higher-margin regulated markets. Optimistic given working capital cycle and RM inflation.
EBITDA FY30 30%+ (with biosimilar/hormone mix)
LowUncertain pricing power for biosimilars post-patent expiry; hormone margins not quantified. Management hedged: 'definitely higher but can't predict now'.
FY27 ₹185-190 Cr (hormone ₹70, oncology ₹50, BE ₹25-30, WC ₹20, R&D ₹10-15)
HighHormone plant Nov 2026 completion, oncology expansion March 2027, BE programs ongoing. Funded from internal cash.
FY28-29 ₹150 Cr for biosimilar clinical trials (3 molecules, 1.5-2 years each)
MediumWill be stretched over Q3 FY28 to Q4 FY29. Deferred expense cycle; not impacting FY27-28 immediately.
Risks the call surfaced
Regulatory execution (registrations)
HighManagement targets 6-7 registrations Q2+, 60-70 in 3 quarters total. But Q1 oncology delayed to Q4. Each ₹1.5-2 Cr revenue per product; 6-7/qtr miss would compress ₹50-100 Cr from FY27-28 guidance.
Working capital & receivables
MediumFY26 debtor days peaked at 208 days due to geopolitical disruption. Current target 165-170 days by FY27-end = ₹300 Cr (40% of ₹700 Cr revenue) in receivables. Further disruption (Suez Canal, sanctions) could extend to 180-200 days, worsening cash conversion.
Gross margin compression
MediumQ1 gross margin 53% down from 56-57% prior quarter. At ₹700 Cr revenue guidance, management expects 49-51% gross margins (vs legacy 60%+). Ideal 47% only at much higher scale. This ₹100-150 Cr EBITDA headwind vs prior expectations.
Oncology & biosimilar execution
HighOncology registrations delayed to Q4 (was Q3). Hormone plant commissioning Nov, GMP only June 2027, limiting FY27 revenue. Erythropoietin clinical trials start Nov (initially classed as 'immediate', now Nov start = 4-5 month delay from 'end of calendar 2027' claim). Keytruda biosimilar clinical completion 1-1.5 years, CY28 patent expiry leaves narrow window.
Capex and biosimilar investment cycle
MediumThree biosimilar molecules in clinical trials require ₹150 Cr capex spread over Q3 FY28 to Q4 FY29. If FY27-28 revenue targets missed, cash flow from operations may not cover both capex and working capital needs, forcing debt draw.
Management
Score 7/10. Clear on numbers, detailed on dossier model and registration pipelines. Evasive on related-party disclosures (Kaler Biopharma dismissed as 'not active'). Transparency on delays (oncology Q4, biosimilar timelines) good; some hedging on FY29-30 targets masked as 'conservatism'. Met FY27 revenue range (₹162.4 Cr Q1 = ₹649.6 Cr annualized, in line ₹650-700 Cr). Oncology mix missed (20% vs 26% prior), attributed to registration delays not product issues. Margin guidance maintained. No prior missed earnings beats; track record solid but limited history (this is early-stage public company).
1 · Nov 2026
Hormone plant manufacturing license; clinical trials Unit 5 Erythropoietin begin
2 · Q4 FY27
Oncology registrations expected (delayed from prior Q3 target)
3 · Q1 FY28
First hormone/Erythropoietin revenue; Ampho B, Octreotide BE submissions
Near-term catalysts (hormone launch, biologics trials, oncology registrations) deferred to FY28-FY30; execution risk on registrations and regulatory timelines remains the key constraint.
Kwality Pharma Q1FY27: consolidated PAT surges 115% YoY to ₹25.6 Cr, margins expand, guidance raised
PAT +115% YoY · revenue +45.6% · margins expanding
₹162.35 Cr
+45.6% YoY
₹25.62 Cr
+115% YoY
15.72%
+5.1pp YoY
₹24.69
Kwality Pharmaceuticals posted consolidated revenue of ₹162.35 Cr in Q1FY27, up 45.6% YoY from ₹111.48 Cr and up 3.3% QoQ from ₹157.11 Cr. Consolidated PAT rose to ₹25.62 Cr from ₹11.92 Cr a year ago (+115% YoY; +1.2% QoQ), with net margin expanding to 15.7% from 10.7% YoY. No exceptional items sit in either the current or year-ago quarter, so the growth is clean/organic rather than base-effect driven. Standalone tracks consolidated almost exactly this quarter (PAT ₹25.63 Cr, EPS ₹24.70 vs consolidated EPS ₹24.69) — the foreign subsidiary contributes negligibly.
Q1 FY-2027 vs prior quarters
The margin expansion is EBITDA-led: EBITDA rose to ₹41 Cr from ₹37 Cr YoY (+13%), with OPM widening to ~25.3% from 21.7% a year ago and 24.8% last quarter, which management attributes to operating leverage and a mix shift toward higher-margin regulated-market and oncology products rather than to lower input costs or other income (other income was flat at ₹0.62 Cr).
The stock went into the print at ₹2,851.45, up 9.1% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 4 consecutive quarters; revenue is at a 6-quarter high.
Management provided strong forward-looking guidance, projecting revenue of INR650-700 crores for FY27, with an aspiration to reach INR1,000 crores by FY29. EBITDA margins are expected to improve from 24% in FY26 to 26-27% in FY27, reaching 30% by FY29, driven by a shift towards higher-margin regulated markets and oncol
— This quarter: beat
There is no independent street coverage or consensus estimate available for this small-cap (~₹335 Cr market cap) name, so vs-street cannot be assessed; the only outside benchmark is management's own prior quarterly pacing guide of ₹150-160 Cr for Q1, which the ₹162.35 Cr print exceeds. Against the FY26-concall guidance of FY27 revenue ₹650-700 Cr and EBITDA margin 26-27%, this quarter's run-rate is tracking ahead — management used this print to raise full-year guidance to revenue ₹700+ Cr, EBITDA ₹189-196+ Cr (27-28%+ margin) and PAT ₹109+ Cr (~15.5%+ margin), i.e., the company itself signals the quarter beat its own plan. Operationally, the quarter's R&D output (13 bioequivalence studies completed toward a 40-molecule pipeline, filings live in 15+ countries) and 15+ new product registrations across Malaysia, Algeria, Peru and Mexico support the regulated-market push cited as the margin driver; CDSCO clearance for Pembrolizumab pre-clinical batches adds a second biologics candidate behind Erythropoietin, which management flagged in the prior concall as a long-term margin lever via the FY29 hormones/biologics revenue ambition. The Hormone facility remains on schedule for a November 2026 completion, the next concrete checkpoint against that plan.
W1
FY27 revenue run-rate against the newly raised ₹700+ Cr guidance — Q1 delivered ₹162.35 Cr, roughly 23% of the full-year target
W2
OPM trajectory toward management's 27-28%+ FY27 target from the current 25.3%
W3
Hormone manufacturing facility completion, targeted for November 2026, as the next milestone toward the ₹200 Cr incremental hormones/biologics revenue management is targeting by FY29
Figures converted from ₹ Lakh (source) to ₹ Cr by /100; no exceptional items in current or either comparison quarter (only FY26 full year carried a ₹82.94L exceptional item); consolidated total PAT ₹25.622 Cr splits to owners ₹25.6245 Cr and NCI -₹0.0022 Cr via foreign subsidiary Kwality Pharmaceuticals Africa Limitada (immaterial, ~₹0.0045 Cr quarterly loss per auditor note); standalone and consolidated are near-identical this quarter.